The diverse roles of protein kinase C-␦ (PKC␦) in cellular growth, survival, and injury have been attributed to stimulus-specific differences in PKC␦ signaling responses. PKC␦ exerts membrane-delimited actions in cells activated by agonists that stimulate phosphoinositide hydrolysis. PKC␦ is released from membranes as a Tyr 313 -phosphorylated enzyme that displays a high level of lipid-independent activity and altered substrate specificity during oxidative stress. This study identifies an interaction between PKC␦'s Tyr 313 -phosphorylated hinge region and its phosphotyrosine-binding C2 domain that controls PKC␦'s enzymology indirectly by decreasing phosphorylation in the kinase domain ATP-positioning loop at Ser 359 . We show that wild-type (WT) PKC␦ displays a strong preference for substrates with serine as the phosphoacceptor residue at the active site when it harbors phosphomimetic or bulky substitutions at Ser 359. In contrast, PKC␦-S359A displays lipid-independent activity toward substrates with either a serine or threonine as the phosphoacceptor residue. Additional studies in cardiomyocytes show that oxidative stress decreases Ser 359 phosphorylation on native PKC␦ and that PKC␦-S359A overexpression increases basal levels of phosphorylation on substrates with both phosphoacceptor site serine and threonine residues. Collectively, these studies identify a C2 domainpTyr 313 docking interaction that controls ATP-positioning loop phosphorylation as a novel, dynamically regulated, and physiologically relevant structural determinant of PKC␦ catalytic activity. P rotein kinase C-␦ (PKC␦) is a serine/threonine kinase that plays a key role in signal transduction pathways that control a wide range of cellular responses. PKC␦ contains a highly conserved C-terminal catalytic domain and N-terminal regulatory C1 and C2 domains. The C1 domain binds lipids and anchors fulllength PKC␦ to membranes. The functional role of the C2 domain has remained more elusive. While C2 domains of conventional PKC (cPKC) isoforms function as calcium-regulated membranetargeting modules, the PKC␦ C2 domain is a topological variant that does not coordinate calcium or bind lipids (1). Rather, it has been characterized as a protein-protein interaction motif (2, 3), with recent evidence that the PKC␦-C2 domain is a phosphotyrosine (pY) binding motif that binds the consensus sequence (Y/
P
rotein kinase C-␦ (PKC␦) is a serine/threonine kinase that plays a key role in signal transduction pathways that control a wide range of cellular responses. PKC␦ contains a highly conserved C-terminal catalytic domain and N-terminal regulatory C1 and C2 domains. The C1 domain binds lipids and anchors fulllength PKC␦ to membranes. The functional role of the C2 domain has remained more elusive. While C2 domains of conventional PKC (cPKC) isoforms function as calcium-regulated membranetargeting modules, the PKC␦ C2 domain is a topological variant that does not coordinate calcium or bind lipids (1) . Rather, it has been characterized as a protein-protein interaction motif (2, 3) , with recent evidence that the PKC␦-C2 domain is a phosphotyrosine (pY) 
binding motif that binds the consensus sequence (Y/ F)-(S/A)-(V/I)-pY-(Q/R)-X-(Y/F) (4).
PKC␦ is allosterically activated by lipids (diacylglycerol [DAG] or phorbol esters such as phorbol 12-myristate 13-acetate [PMA] ) that bind to the C1 domain. PKC␦ also is dynamically regulated as a result of tyrosine phosphorylation by Src (5, 6) . We previously showed that oxidative stress releases PKC␦ from membranes, activates Src, and induces a global increase in PKC␦ phosphorylation at Tyr 313 and Tyr 334 in both soluble and particulate subcellular compartments (7) . These residues in the V3 hinge region of human PKC␦ correspond to Tyr 311 and Tyr 332 in rodent PKC␦. The nomenclature for human PKC␦ is used below. While PMA does not increase Src activity, it delivers PKC␦ in an active conformation to Src-enriched caveolar membranes where a low level of basal Src activity is sufficient to promote PKC␦ phosphorylation at Tyr 313 but not Tyr 334 (8) . Since PKC␦ is phosphorylated by Src in vitro at both Tyr 313 and Tyr 334 (9) , a mechanism that might account for the selective PMA-dependent PKC␦ phosphorylation at Tyr 313 but not Tyr 334 has never been obvious. Stimulus-induced increases in PKC␦-Tyr 313 phosphorylation have been implicated in several PKC␦-dependent cellular responses (10, 11) . We previously showed that Tyr 313 phosphorylation influences PKC␦ activity toward cardiac troponin I (cTnI, the inhibitory subunit of the troponin complex and a physiologically important PKC␦ substrate in cardiomyocytes) (9) . cTnI contains several phosphorylation clusters that exert distinct effects on cardiac contraction. PKC␦ phosphorylates cTnI at Ser 23 /Ser 24 when allosterically activated by phosphatidylserine (PS)/PMA; studies in detergent-extracted single cardiomyocytes link cTnI-Ser 23 / Ser 24 phosphorylation to a decrease in tension at submaximum, but not maximum, calcium concentrations. When PKC␦ is tyrosine phosphorylated by Src, PKC␦ acquires cTnI-Thr 144 kinase activity: it phosphorylates cTnI at both Ser 23 /Ser 24 and Thr 144 , leading to a decrease in maximum tension and cross-bridge kinetics (i.e., a different functional response). Additional studies showing that the Src-dependent acquisition of cTnI-Thr 144 kinase activity is completely abrogated by a Y313F substitution implicates Tyr 313 phosphorylation as the mechanisms underlying the Srcdependent increase in PKC␦ activity (9) .
The structural basis for Tyr 313 phosphorylation-dependent changes in PKC␦'s enzymology is not obvious. This study builds upon the intriguing observation that Tyr 313 resides in a PKC␦-C2 domain consensus-binding motif (VGI-Y 313 -QGF) (4) to show that the C2 domain interacts with the Tyr 313 -phosphorylated V3 region and that this interaction controls PKC␦ catalytic activity indirectly by regulating phosphorylation at Ser 359 , a novel phosphorylation site in the Gly-rich ATP-positioning loop (G loop, also known as the phosphate binding P loop) of the kinase domain. 334 antibodies were from Santa Cruz Biotechnology. Mouse monoclonal anti-green fluorescent protein (anti-GFP) 3E6 was from Invitrogen. Anti-Flag was from Sigma. All other antibodies were from Cell Signaling Technology. The specificity of all anti-PKC␦ antibodies (including phosphorylation site-specific antibodies that specifically recognize phosphorylation at Thr 507 , Tyr 313 , and Tyr 334 ) has been validated previously (9) . Src was from Invitrogen-Life Technologies. CREBtide and other peptide substrates were from Anaspec. PMA was from Sigma. Other chemicals were reagent grade.
MATERIALS AND METHODS

Materials. PKC␦ and PKC␦-pTyr
Plasmids and cell lines. Mutant constructs of the PKC␦-enhanced GFP (EGFP) expression plasmid (human sequence with EGFP fused to its C terminus) (9) were generated by PCR and validated by sequencing. N-terminal Flag-tagged versions of PKC␦, PKC␦-⌬C2 (where ⌬C2 represents a C2 deletion of amino acids [aa] 1 to 123 [⌬1-123]), and PKC␦-S359A also were generated and inserted into pcDNA3.1. All results shown in Fig. 2 and 3 with EGFP-tagged enzymes were replicated with Flagtagged enzymes. Expression vectors were introduced into HEK293 cells (maintained in Dulbecco's modified Eagle's medium [DMEM] with 10% fetal bovine serum [FBS]) using Effectene transfection reagent (Qiagen) according to the manufacturer's instructions. Cells were lysed after 24 h in homogenization buffer containing 20 mM Tris-Cl (pH 7.5), 0.05 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.2% Triton X-100, 5 g/ml aprotinin, 5 g/ml leupeptin, 5 g/ml benzamidine, 1 mM phenylmethylsulfonyl fluoride, and 5 M pepstatin A.
Cardiomyocytes were isolated from the hearts of 2-day-old Wistar rats and infected with adenoviral vectors that drive expression of wild-type PKC-␦ (WT-PKC␦) or PKC␦-S359A according to methods published previously (12) . Total cell lysates and fractions enriched in myofibrillar proteins were prepared according standard methods described in previous publications (7, 13) . The study was approved by Columbia University's Institutional Animal Care and Use Committee.
Preparation of caveolar membranes. Caveolar membrane proteins were isolated according to a detergent-free purification scheme that was described previously (14) .
IVKAs and Western blotting. In Vitro kinase assays (IVKAs) were performed with PKC␦ immunoprecipitated with anti-GFP or anti-Flag from 150 g of starting cell extract according to methods described previously (9) . Incubations were performed for 30 min at 30°C in 110 l of reaction buffer containing 30 mM Tris-Cl, pH 7.5, 5.45 mM MgCl 2 , 0.65 mM EDTA, 0.65 mM EGTA, 0.1 mM DTT, 1.09 mM sodium orthovanadate, 0.1 M calyculin, 0.55 M protein kinase inhibitor (PKI), 217 mM NaCl, 3.6% glycerol, 89 g/ml phosphatidylserine plus 175 nM PMA, and [␥-32 P]ATP (10 Ci, 66 M) with 4 g of Tn complex (consisting of equimolar cTnI, cTnT, and cTnC) as the substrate. Immunoblotting on lysates or immunoprecipitated PKC␦ was according to methods described previously or to the manufacturer's instructions. In each figure, each panel represents the results from a single gel (exposed for a uniform duration); detection was with enhanced chemiluminescence.
32 P incorporation was quantified by phosphorimager, and PKC␦ phosphorylation was normalized to PKC␦ protein levels.
Peptide kinase assays were carried out in a similar manner in 200 l of a reaction mixture containing 26 mM Tris, pH 7.5, 5 mM MgCl 2 , 0.6 mM EGTA, 0.6 mM EDTA, 0.5 M PKI, 10 M protein phosphatase 1 (PP1), 0.25 mM DTT, 89 g/ml phosphatidylserine plus 175 nM PMA, and 50 M peptide substrate, as indicated in the legend of Fig. 6 . Reactions were initiated by the addition [␥-
32 P]ATP (10 Ci, 66 M) and were performed in quadruplicate at 30°C for 15 min. Assays were terminated by placing samples on ice, which was followed by centrifugation at 1,500 ϫ g for 10 min at 4°C. Forty microliters of each supernatant was spotted onto phosphocellulose filter papers (P-81), which were dropped immediately into water and washed (five times for 5 min), and radioactivity counts were determined.
Multiple-reaction monitoring (MRM) phosphorylation of PKC␦. WT-PKC␦ and PKC␦-⌬C2 enzymes were heterologously overexpressed in HEK293 cells, immunoprecipitated for IVKAs, and then subjected to in-gel digestion as described previously (15) . Briefly, WT-PKC␦ and PKC␦-⌬C2 bands separated by SDS-PAGE were excised, cut into 1-mm pieces, and washed three times with 50% acetonitrile-25 mM ammonium bicarbonate for 15 min with shaking. Gel pieces were incubated with 25 mM ammonium bicarbonate plus 10 mM dithiothreitol for 60 min at 55°C, washed with acetonitrile (ACN), and then incubated with 25 mM ammonium bicarbonate plus 55 mM iodoacetamide (freshly made) for 30 min in the dark. Gel pieces were then washed with ACN, dried, rehydrated with 10 ng/l trypsin (sequencing grade; Promega) in 25 mM ammonium bicarbonate, and then placed on ice for 30 min. Excess trypsin was removed, and then 20 l of 25 mM ammonium bicarbonate was added. Samples were digested at 37°C for 18 h. The liquid was transferred to a clean tube. The peptides were extracted twice using 50% ACN-0.1% trifluoroacetic acid (TFA) for 20 min at 25°C with shaking. The final peptide mixture was subjected to C 18 reverse-phase chromatography in C 18 ZipTips (Millipore) using 0.1% TFA. The peptides were then eluted two times with 20 l of 70% ACN-0.1% TFA and 95% ACN-0.1% TFA. The combined solution was dried using a SpeedVac vacuum centrifuge (Thermo Electron) and frozen at Ϫ80°C until analysis.
MRM assays were developed, optimized, and validated using a nanoliquid chromatography-tandem mass spectrometry (nano-LC-MS/MS) system, the 4000 QTRAP hybrid triple-quadrupole/linear ion trap mass spectrometer (AB Sciex). Peptides obtained from the in-gel digestion of PKC␦ proteins were reconstituted in 20 l of 0.1% formic acid. Peptides were separated by an Eksigent Tempo nano-LC system (Eksigent Technology) onto a BioBasic C 18 reverse-phase PicoFrit column (300-Å pore size, 5-m particle size, 75-m inner diameter by 10-cm length, 15 [vol/vol] formic acid) at a 500 nl/min flow rate on the 4000 QTRAP MS system, with the NanoSpray source spray head coupled to a distal coated PicoTip fused silica spray tip (360-m outside diameter, 75-m inside diameter, 15-m emitter orifice diameter; New Objective). Samples were analyzed using the following settings: curtain gas (CUR), 15; collision gas (CAD), high; ion spray voltage (IS), 2.5 kV; ion source gas 1 (GS1), 25; ion source gas 2 (GS2), 0; resolution Q1 and Q3, unit; heater interface temperature, 150°C. Each sample was run in triplicate. Peak detection and quantification of peak area were determined with Multiquant software, version 2.0, and inspected manually to ensure correct peak identification and quantification. Quantification of PKC␦ phosphosites was carried out using a ratio of the peak area to gel band densitometry.
FRET sensor data. The C2 domain of PKC␦ (123 aa) was cloned from full-length human PKC␦ cDNA. All constructs contain an N-terminal Flag tag immediately followed by mCitrine. In sequence behind the mCitrine are the C2 domain of PKC␦, 10-nm ER/K ␣-helix linker (16), a tobacco etch virus (TEV) protease site (ENLYFQ), mCerulean, and a 13-amino-acid peptide sequence containing a Tyr residue that when phosphorylated corresponds to a C2 domain consensus binding site. Fluorescent resonance energy transfer (FRET) sensors were generated with either the optimal binding sequence MALYSIYQPYVFA (4), the native PKC␦ SEPVGIY 313 QGFEKK sequence, or these sequences with Tyr¡Phe (in boldface) substitutions (MALYSIFQPYVFA and SEPVGIFQGFEKK) as controls. All domains and fluorophores are linked with three to four GlySer-Gly repeats to allow rotational flexibility and are cloned between unique restriction sites. A C2 domain H62D mutation was generated by site-directed mutagenesis (QuikChange; Stratagene). These constructs were cloned between unique restriction sites in pBiex-1 vector and used for expression in Sf9 cells. Proteins were purified as described previously (17) . FRET spectra for recombinant proteins were acquired on a FluoroMax-4 fluorometer (Horiba Scientific). Samples were excited at 430 nm (spectral band pass [bp 8 nm]), and emission was scanned from 450 to 650 nm (bp 4 nm). All samples were suspended in a buffer composed of 50 mM Tris-HCl, 10 mM MgCl 2 , 10% glycerol, and 2.5 mM DTT. Recombinant Src kinase was added to the reaction samples and incubated at 30°C for 30 min before spectra were taken. The samples also contain 0.05 mg/ml bovine serum albumin (BSA) to limit nonspecific surface adsorption of sensor proteins.
RESULTS
A FRET-based sensor detects a C2 domain interaction with a pTyr 313 -bearing peptide. Since traditional bimolecular approaches are unlikely to be an effective approach to detect a cis interaction between the C2 domain and the pTyr 313 motif (which is predicted to be facilitated by the tethering of the two domains within full-length PKC␦), we generated FRET-based sensors consisting of a single polypeptide with (N to C terminus) the C2 domain, mCerulean (as FRET donor), an ER/K linker (18), a 13-residue peptide based upon either a previously described optimal pTyr binding motif (4) or sequence flanking Tyr 313 in PKC␦, and mCitrine (as a FRET acceptor). These sensors are designed to primarily report on the strength of the interaction between the C2 domain and the peptide (higher FRET indicates a stronger interaction) (Fig. 1A) (16) . Sensors were purified and subjected to in vitro kinase assays with recombinant Src. Figure 1B and C show that the FRET signals for sensors bearing either the optimal pTyr binding motif or the Tyr 313 -bearing peptide increase as a result of in vitro phosphorylation by Src. Two sets of control sensors were generated to establish the specificity of the FRET signals (Fig. 1C) . First, studies with sensors containing Tyr¡Phe substitutions at each peptide's phosphorylation site establish that the increase in FRET signal is due to phosphorylation at the designated tyrosine residue in the peptide. Second, studies with sensors containing H62D substitutions in the C2 domain pTyr binding pocket (that disrupts the C2 domain-pTyr interaction) (schematic in Fig. 1D ) (4) point to a phosphorylation-dependent interaction with the C2 domain. These results indicate that the Src-dependent increases in FRET are due to C2 domain interactions with Tyr-bearing peptides, providing direct evidence for an interaction between the C2 domain and the pTyr 313 motif in the V3 hinge of PKC␦. The C2 domain is required for in vivo PMA-dependent PKC␦-Tyr 313 phosphorylation. We used a PKC␦-C2 domain deletion construct (PKC␦-⌬C2) to examine the consequences of C2 domain-dependent interactions in a cellular context. Figure 2A shows that WT-PKC␦ and PKC␦-⌬C2 are expressed at similar levels in HEK293 cells and that both enzymes undergo similar maturational phosphorylations at the activation loop ( Fig. 2A and B ). Control studies indicate that the effect of the C2 domain deletion to prevent PMA-dependent Tyr 313 phosphorylation is not due to a defect in PKC␦ targeting to Src-enriched caveolar membranes. Figure 2C shows that WT-PKC␦ and PKC␦-⌬C2 both translocate to the caveolar membrane fraction. These results indicate that some other mechanism must account for the selective defect in PMA-dependent PKC␦-⌬C2-Tyr 313 phosphorylation. Therefore, we considered whether a C2 domain deletion disrupts the docking interaction that protects the phosphorylation site at Figure 3 shows that WT-PKC␦ executes a time-dependent autophosphorylation reaction. This is tracked as an increase in 32 P incorporation, which provides an integrated measure of autophosphorylation and (where specified) PKC␦ tyrosine phosphorylation by Src (Fig. 3) ; a representative autoradiogram is depicted on the left, with the results of three separate experiments quantified on the right. PKC␦ autophosphorylation also is detected by immunoblot analysis with an anti-pTXR motif phosphorylation site-specific antibody (PSSA) that specifically recognizes one of several autophosphorylation sites on PKC␦ at Thr 295 (19) . It is important to note that Thr 295 autophosphorylation is tracked in this study solely as a convenient readout of PKC␦ autocatalytic activity. Studies to date show that a T295A substitution (in the vicinity of Tyr 313 ) leads to a defect in Src-dependent PKC␦-Tyr 313 phosphorylation (and therefore prevents the Src-dependent increase in PKC␦ catalytic activity) but that a T295A substitution does not otherwise grossly influence PKC␦ catalytic activity. Insofar as this study focuses on mechanisms that activate PKC␦ downstream from Src (that bypass the requirement for phosphorylation at Tyr 313 ) (see below), a regulatory role for Thr 295 autophosphorylation is unlikely and was not considered. Figure 3 shows that WT-PKC␦ executes a time-dependent autophosphorylation and that autophosphorylation (quantified as 32 P incorporation) is enhanced by Src, consistent with previous evidence that Src enhances PKC␦'s autocatalytic activity.
The kinetics of PKC␦ phosphorylation of cTnI and cTnT were examined in parallel (note that cTnC is not a substrate for PKC). Figure 3 shows that the time course for WT-PKC␦ phosphorylation of individual sites on cTnI is strikingly different. The C2 domain controls phosphorylation of the ATP-positioning loop at Ser 359 . WT-PKC␦ and PKC␦-⌬C2 were subjected to IVKAs and then targeted multiple-reaction monitoring (MRM)-mass spectrometry to determine whether PKC␦-⌬C2's altered enzymology is attributable to a change in phosphorylation. We identified a novel phosphorylation site at Ser 359 in the highly conserved Gly-rich ATP-positioning loop (G loop, also known as the phosphate positioning P loop) in the small lobe of the kinase domain (see Fig. S1 in the supplemental material). Quantification (peak areas) showed that the Ser 359 -phosphorylated peptide is detected by MRM in tryptic digests from WT-PKC␦ but that it is not detected in digests from PKC␦-⌬C2 (see Fig. S1A , B, E, and F in the supplemental material). The precise stoichiometry of phosphorylation at this site could not be assessed since unphosphorylated Ser 359 peptide ionizes poorly in the MS instrument; it is detected (elution time, ϳ16 min), but the levels are below the lower limit of quantification.
We developed an anti-PKC␦-pSer 359 PSSA as a separate strategy to track PKC␦ G-loop phosphorylation. Figure 3B shows the validation of this reagent; the anti-PKC␦-pSer 359 PSSA recognizes WT-PKC␦ but not a PKC␦-S359A mutant. Western blots using this reagent show that Ser 359 phosphorylation is detected on WT-PKC␦ but not on the PKC␦-⌬C2 mutant (Fig. 3B) . Separate experiments showed that WT-PKC␦ or PKC␦-⌬C2 phosphorylation at Ser 359 does not grossly change during the IVKA (data not shown). This contrasts with phosphorylation at Thr 295 , which increases during IVKAs on both WT-PKC␦ and PKC␦-⌬C2 (Fig. 3A) . The Thr 295 -phosphorylated peptide also was detected in the MRM studies, where the quantification showed a 37% higher level of the Thr 295 -phosphorylated peptide in tryptic digests from PKC␦-⌬C2 than in the digest from WT-PKC␦ (see Fig. S1A Figure 4 shows that WT-PKC␦ activity is strictly lipid dependent, but PKC␦-S359A possesses a considerable amount of lipidindependent autocatalytic activity, detected as a high level of lipidindependent autophosphorylation at Thr 295 ( Fig. 4A ) and 32 P incorporation (Fig. 4B) . The S359A substitution also increases lipid-independent cTnI-Ser 23 /Ser 24 kinase activity (relative to WT-PKC␦), and it confers Src-independent cTnI-Thr 144 and cTnT-TXR kinase activity. PS/PMA treatment results in further increases in PKC␦-S359A activities.
PKC␦-S359E also possesses a modest level of lipid-independent autocatalytic activity (detected as increased Thr 295 autophos- F12) , and the insoluble pellet (P) that are separated by a detergent-free caveolar purification scheme (C). It should be noted that the bands representing WT-PKC␦ and PKC␦-⌬C2 were aligned for presentation purposes in panels A and B; the increased electrophoretic mobility due to the C2 domain deletion was observed in all experiments and can be observed in panel C. All results were replicated in three to six separate experiments on separate culture preparations. Each panel shows results from a single gel exposed for a uniform duration. phorylation and 32 P incorporation into the enzyme) ( Fig. 4A and  B) . The observation that S¡E and S¡A substitutions both increase lipid-independent PKC␦ autocatalytic activity suggests that an electrostatic interaction involving the Ser 359 hydroxyl group (rather than Ser 359 phosphorylation) stabilizes the inactive conformation of the enzyme. However, S359A and S359E substitutions exert very different effects on Tn phosphorylation. PKC␦-S359E retains wild-type cTnI-Ser 23 /Ser 24 kinase activity, but it does not phosphorylate cTnI at Thr 144 or cTnT at TXR motifs (even when it is Tyr 313 phosphorylated by Src). While a PKC␦-S359E-dependent increase in 32 P incorporation into cTnT was detected in assays with Src (Fig. 4B) , this was mapped to a different cTnT phosphorylation site that is recognized by an anti-PKC substrate motif PSSA (that recognizes pS flanked by R or K at Ϫ2 and ϩ2 positions) (Fig. 4A) ; cTnT's PKC phosphorylation cluster contains a site (T 194 ERKS 198 GKRQT 203 ER; the phosphorylation site is underlined, and the boldface R at the Ϫ2 position and K at the ϩ2 position relative to the phosphorylation site show that this conforms to the described PKC consensus motif) that conforms to this motif.
The antithetical effects of S359A and S359E substitutions on PKC␦'s TXR kinase activity could suggest a role for a negative charge (e.g., phosphorylation) at this site. However, Fig. 4C shows that a position 359 bulky/uncharged Leu substitution also abrogates cTnI-Thr 144 and cTnT-TXR motif phosphorylation, without disrupting PKC␦ autocatalytic activity or cTnI-Ser 23 /Ser 24 kinase activity. These results argue that the steric bulk of a position 359 phosphate group (rather than the negative charge) disrupts PKC␦ activity toward cTnI-Thr 144 and cTnT-TXR motifs. We introduced an S359E substitution into the PKC␦-⌬C2 backbone to test whether the C2 domain controls PKC␦ catalytic activity indirectly by regulating Ser 359 phosphorylation. Figure 4D shows that PKC␦-⌬C2 and PKC␦-⌬C2-S359E display similar cTnI-Ser 23 /Ser 24 kinase activities. PKC␦-⌬C2 (which is not detectably phosphorylated at Ser 359 ) displays high levels of cTnIThr 144 and cTnT-TXR motif activity. cTnI-Thr 144 and cTnT-TXR motif phosphorylation is completely abrogated by an S359E substitution in the PKC␦-⌬C2 backbone.
These studies (summarized in Fig. 5 ) implicate Ser 359 as a novel PKC␦ phosphorylation site that plays a heretofore unrecognized . Src also induces parallel increases in WT-PKC␦ and PKC␦-⌬C2 phosphorylation at Tyr 334 ; these immunoblots have been omitted from the figure since we previously demonstrated that Tyr 334 phosphorylation does not contribute to the control of PKC␦ catalytic activity (9) . Immunoblotting was performed for cTnI phosphorylation at Ser 23 /Ser 24 , cTnI phosphorylation at Thr 144 (detected with an anti-pTXR motif PSSA) (9), and cTnT phosphorylation at TXR motifs (bottom left). The schematic shows PKC phosphorylation sites on cTnI and cTnT. Results for 32 P incorporation into PKC␦, cTnI, and cTnT are quantified (n ϭ 3) (right). Results in each panel are normalized to phosphorylation levels detected in assays with WT-PKC␦ activity. Results are presented as the means Ϯ standard errors and are analyzed with a Student's t test with a Bonferroni correction for multiple comparisons (*, P Ͻ 0.05). (B) WT-PKC␦, PKC␦-⌬C2, or PKC␦-S359A was immunoprecipitated from HEK293 cells and subjected to immunoblot analysis with a PSSA that specifically recognizes phosphorylation at Ser 359 or PKC␦ protein (to validate equal protein loading).
role to control phosphorylation of TXR motifs on cTnI and cTnT (but not cTnI phosphorylation at Ser 23 /Ser 24 ). However, these newer results also raise a question regarding the mechanism underlying our original observation that Src increases WT-PKC␦'s in vitro TXR activity; Src-phosphorylated WT-PKC␦ acquires TXR activity without any gross change in its Ser 359 phosphorylation status in the IVKAs (an artificial context that does not include cellular phosphatases). The simplest, most parsimonious, explanation for this finding is that WT-PKC␦ TXR activity arises from a pool of enzyme that is recovered without G-loop Ser 359 phosphorylation. This formulation is consistent with (i) the MRM-MS studies that detected, but could not quantify, the unphosphorylated Ser 359 peptide and (ii) the mutagenesis studies showing that TXR activity is completely abrogated by the phosphomimetic or bulky Ser 359 substitutions, indicating that an unphosphorylated, or alanine substituted, Ser 359 in the G loop is necessary for TXR activity. In fact, the data shown in Fig. 3 showing that WT-PKC␦ displays a very low level of Src-independent TXR activity when incubations are pushed to very prolonged intervals suggest that TXR activity reflects both the fraction of total enzyme that is recovered without Ser 359 phosphorylation and its overall catalytic activity and that Src increases WT-PKC␦'s TXR activity by enhancing its catalytic activity (independent of any effect on Ser 359 phosphorylation). We performed additional studies with the PKC␦-Y313F mutant enzyme (which prevents phosphorylation by Src but does not influence G-loop Ser 359 phosphorylation) (see Fig.  8C ) to test this hypothesis. The observation that a Y313F substitution decreases PKC␦ autophosphorylation at Thr 295 (53% Ϯ 7% relative to WT-PKC␦; P Ͻ 0.05, n ϭ 3) indicates that an Src-driven conformational change, which may or may not involve the C2 domainpTyr 313 docking interaction, contributes to the mechanism for maximal activation of WT-PKC␦.
An S359A substitution influences the phosphoacceptor preference of PKC␦. While PKC␦ is generally viewed as an Ser/Thr 32 P incorporation was quantified by phosphorimager analysis for assays performed with WT-PKC␦ (n ϭ 7), PKC␦-S359A (n ϭ 4), and PKC␦-S359E (n ϭ 3). Results are presented as the means Ϯ standard errors and are analyzed with Student's t test with a Bonferroni correction for multiple comparisons (*, P Ͻ 0.05). Note that the apparent difference between the PS/PMA-dependent increases in WT-PKC␦-Thr 295 phosphorylation in the two IVKAs in panel A is attributable to a difference in exposure times: optimal exposure times were considerably shorter for studies that compared WT-PKC␦ with the highly active PKC␦-S359A mutant than for studies that compared WT-PKC␦ with PKC␦-S359E (which have more similar autocatalytic activities).
kinase, substrate sequence logos suggest a clear preference for substrates with an Ser at the phosphoacceptor site (P site). Of note, structural studies of PKA complexed with ATP and PKI (an inhibitor peptide that docks to the active site) place the Ser in the GK GSFG sequence at the tip of the G loop in close proximity to the P site on substrates (Fig. 6A) . Our observation that an S359A substitution (at the tip of the G loop of PKC␦) selectively increases phosphorylation of TXR (Thr-directed) motifs on cTnI and cTnT provided a rationale to test whether posttranslational modifications (PTMs) at Ser 359 specifically regulate substrate phosphorylation at Thr (but not Ser) residues. We compared WT-PKC␦ and PKC␦-S359A activity toward short peptide substrates based upon the cTnI phosphorylation site at position 144 with either Thr or Ser at the P site. It is worth noting that IVKAs described in the previous sections tracked WT-PKC␦ phosphorylation of proteins in the troponin complex; these assays are performed at limiting/ submicromolar substrate concentrations since practical issues related to cost and protein insolubility preclude the use of higher concentrations of protein substrates. In contrast, peptide kinase assays are performed at a considerably higher substrate concentration (50 M) and expose a low level of cTnI-Thr 144 phosphorylation by PKC␦. However, Fig. 6B shows that WT-PKC␦ displays a considerably higher level of activity toward the cTnI-Ser 144 peptide. Moreover, the S359A substitution increases peptide kinase activity. PKC␦-S359A phosphorylates both cTnI-Thr 144 and cTnI-Ser 144 peptides; it does not discriminate between these peptides. Similar results were obtained in assays with peptides based upon the Ser 133 phosphorylation site in CREB, which is flanked by a different phosphorylation motif (Fig. 6C) . In this case, WT-PKC␦ and PKC␦-S359A display high levels of activity toward the CREB-Ser 133 peptide. An S133T substitution markedly decreases peptide phosphorylation by WT-PKC␦ but not PKC␦-S359A. These results implicate PTMs at Ser 359 in PKC␦'s G loop as a mechanism that regulates PKC␦'s P-site specificity.
G-loop regulation of PKC␣ and PKA activities. The G-loop Ser 359 phosphorylation site in PKC␦ is highly conserved in other PKCs and in PKA (Fig. 7) . Since there is recent evidence that this G-loop site is posttranslationally modified in PKC␣ and PKA (20, 21) and since the functional role of this site in PKC␣ and PKA remains uncertain, we examined whether G-loop substitutions influence PKC␣ or PKA catalytic activity. Figure 7B and C show that single-residue substitutions in the G-loops of PKC␣ (at Ser 349 ) or PKA (at Ser 53 ) do not influence enzyme expression or priming/activation loop phosphorylation. WT-PKC␣ displays a modest amount of activity toward cTnI-Ser 23 /Ser 24 in assays with PS/PMA (Fig. 7B) . The S349A substitution increases PKC␣'s lipid-dependent cTnI-Ser 23 /Ser 24 kinase activity, without imparting activity toward cTnI-Thr 144 or cTnT-TXR motifs (and it does not confer lipid-independent catalytic activity). Control studies performed in parallel show that a similar level of cTnI-Ser 23 /Ser 24 phosphorylation by lipid-/Src-activated PKC␦ is associated with considerable amounts of cTnI-Thr 144 and cTnT-TXR activity. Figure 7C shows that an S53A substitution increases while an S53E substitution decreases cTnI-Ser 23 /Ser 24 phosphorylation by PKA. WT and mutant PKA constructs do not phosphorylate TXR sites on cTnI or cTnT. Collectively, these studies implicate G-loop PTMs as general regulators of PKC␦, PKC␣, and PKA activity. In each case, S¡A substitutions increase and S¡E substitutions decrease activity. However, the detailed nature of the regulatory control is kinase specific. The G-loop S¡A substitution confers TXR motif activity on PKC␦ but not on PKC␣ or PKA.
H 2 O 2 decreases PKC␦-Ser 359 phosphorylation in cardiomyocytes; PKC␦-S359A displays an activated phenotype in cardiomyocytes. We examined whether PKC␦-Ser 359 phosphorylation is regulated in cardiomyocytes. Figure 8A shows that endogenous PKC␦ is recovered from cardiomyocytes as a Ser 359 -phosphorylated enzyme and that PKC␦-Ser 359 phosphorylation decreases in association with the H 2 O 2 -dependent increase in PKC␦ phosphorylation at Tyr 313 . PKC␦-pSer 359 immunoreactivity is reduced by 74% Ϯ 4% relative to levels in resting cardiomyocytes following treatment with 5 mM H 2 O 2 (n ϭ 4, P Ͻ 0.05). Figure 8B shows that the reciprocal H 2 O 2 -dependent changes in PKC␦-Tyr 313 and Ser 359 phosphorylation are associated with the acquisition of lipid-independent cTnI-Ser 23 /Ser 24 and cTnI-Thr 144 kinase activities. Figure 8C uses a heterologous overexpression strategy to establish a link between the H 2 O 2 -dependent changes in Tyr 313 and Ser 359 phosphorylation. Figure 8C shows that the H 2 O 2 -dependent decrease in Ser 359 phosphorylation is abrogated by a Y313F substitution.
We used an overexpression strategy with WT-PKC␦ and PKC␦-S359A followed by immunoblotting with the anti-PKC substrate PSSA (as a general screen for target protein phosphorylation), anti-pTXR (a specific screen for phosphorylation at Thr phosphoacceptor sites), and antibodies that recognize activating phosphorylations on protein kinase D (PKD, a PKC␦-activated effector) (22) to examine the functional importance of Ser 359 in a cellular context. Immunoblotting studies on cell lysates show that WT-PKC␦ or PKC␦-S359A overexpression leads to an increase in PMA-dependent responses (Fig. 8D) . However, PKC␦-S359A uniquely acts as a constitutively activated enzyme to enhance (basal) anti-PKC substrate PSSA immunoreactivity and phosphorylation/activation of PKD (Fig. 8D) . PKC␦-S359A overexpression also increases substrate phosphorylation at TXR motifs. However, pTXR motif immunoreactivity was detected on only a limited number of proteins in cell lysates. Therefore, we also assessed phosphorylation in the myofibrillar fraction. Figure 8D shows that WT-PKC␦ and PKC␦-S359A overexpression leads to a marked increase in basal and PMA-dependent anti- PKC substrate PSSA immunoreactivity in the myofibrillar fraction: PKC substrate motif phosphorylation is higher in cardiomyocytes that overexpress PKC␦-S359A than in cardiomyocytes that overexpress WT-PKC␦. The myofibrillar fractions also contain considerable amounts of pTXR immunoreactivity. pTXR immunoreactivity (including on a band that comigrates with cTnT) is considerably higher in the myofibrillar fraction from cardiomyocytes that overexpress PKC␦-S359A than in WT-PKC␦.
DISCUSSION
PKC␦ was originally described as a signaling kinase that mediates growth factor-dependent cellular responses. The original allosteric model of PKC␦ activation focused on translocation events that deliver the enzyme in an active conformation to DAG-enriched membranes. This model assumes that the cellular actions of PKC␦ are membrane delimited and that PKC␦'s catalytic activity is an inherent property of the enzyme that is not altered by the activation process. However, subsequent studies exposed alternative lipid-independent mechanisms for PKC␦ activation that result in the generation of distinct molecular forms of PKC␦ with altered catalytic properties in various subcellular compartments (not just in DAG-enriched membranes). We previously reported that oxidative stress leads to the activation of Src and accumulation of a Tyr 313 -phosphorylated form of PKC␦ with altered catalytic properties in cardiomyocytes (7, 9) . This study identifies the mechanism that links Tyr 313 phosphorylation to changes in catalytic activity by showing that the Tyr 313 -phosphorylated hinge region functions as a docking site for the pTyr binding C2 domain of PKC␦ (schematized in Fig. 9 ).
We used a PKC␦-⌬C2 deletion mutant to examine the functional consequences of C2 domain-mediated docking interactions. First, we showed that full-length PKC␦ phosphorylates cTnI-Thr 144 and cTnT-TXR motifs when it is Tyr 313 phosphorylated by Src. In contrast, PKC␦-⌬C2 possesses a high level of Srcindependent cTnI-Thr 144 and cTnT-TXR motif activity. These results suggest that the C2 domain functions as an autoinhibitory regulator of certain full-length PKC␦ activities and that a docking interaction between the C2 domain and the Tyr 313 -phosphorylated hinge region induces a global conformational change that relieves this C2 domain-mediated autoinhibitory constraint. Second, we showed that the C2 domain regulates PKC␦ activity by controlling phosphorylation at Ser 359 . WT-PKC␦ displays a high level of Ser 359 phosphorylation. Studies The G-loop sequence is highly conserved in many protein kinases. Structural studies of PKA and several PKCs show that the G loop forms a flexible clamp that orients the ␥-phosphate of ATP for transfer to substrate; localized changes in the position of this loop influence the kinetics of nucleotide binding and the phosphoryl transfer reaction. The Ser in the GKGSFG sequence in PKA is strategically positioned at the tip of the G loop at the entrance to the ATP-binding cleft, in close proximity to the P site on substrates (Fig. 7A ). This site in the G loop of several other kinases has been implicated in the control of catalytic activity. For example, CDK1 (a regulator of the eukaryotic cell cycle) is maintained in an inactive conformation by inhibitory phosphorylations at Y 15 and, to a lesser extent, in the adjacent T 14 in its ATP-binding GEGTYG motif; dephosphorylation of these sites at the onset of mitosis leads to enzyme activation (23) . The nononcogenic c-ABL protooncogene is activated by a G-loop GGGQ(Y253F)G substitution (24) ; point mutations in Bcr-Abl (the constitutively active tyrosine kinase that drives malignant transformation in chronic myeloid leukemia) that alter G-loop Y 253 phosphorylation confer drug resistance and enhanced oncogenicity (25, 26) . Finally, there is evidence that c-Raf is maintained in a basal autoinhibited state through G-loop autophosphorylation and that c-Raf becomes activated (leading to a paradoxical activation of the mitogen-activated protein kinase pathway) by ATP-competitive Raf inhibitors that prevent G-loop autoinhibitory phosphorylation (27) . However, posttranslational modifications at the G loop that regulate PKC (or PKA) activities have never been reported. This study identifies G-loop regulation of two key aspects of PKC␦'s enzymology, as follows.
(i) Phosphomimetic or bulky substitutions at Ser 359 inhibit PKC␦ phosphorylation of TXR motifs on cTnI and cTnT but not cTnI phosphorylation at Ser 23 /Ser 24 . Ser 359 phosphorylation could in theory influence PKC␦'s substrate specificity indirectly by restructuring the catalytic pocket to accommodate a wider range of phosphorylation motifs or by modulating docking interactions that control substrate alignment in the catalytic pocket. However, experiments with short peptide substrates harboring single-residue P-site substitutions show that a phosphomimetic substitution at position 359 prevents phosphorylation of Thrphosphoacceptor sites (presumably due to steric clash with the Thr methyl group); Ser-phosphoacceptor sites are not affected. Hence, while recent literature has focused on consensus phosphorylation motifs (residues that are either preferred or deselected at positions flanking the P site on a particular substrate) as the key determinant of enzyme substrate specificity, our studies show that PKC␦ activity can also vary depending upon whether the P site is a Ser or Thr residue. The novelty of this observation deserves emphasis. While Chen et al. recently identified the "DFG ϩ1" residue (a residue immediately downstream of a conserved Asp-Phe-Gly sequence) in the activation segment as a structural determinant that defines the inherent P-site specificity of various Ser/Thr kinases (28), a dynamically regulated posttranslational modification that can alter P-site specificity in a stimulus-specific manner is unprecedented. This study implicates ATP-positioning loop phosphorylation at Ser 359 as a mechanism that dynamically regulates the P-site specificity of PKC␦.
(ii) An S359A substitution imparts a high level of lipid-independent catalytic activity. The PKC␦-S359A mutant is a constitutively active enzyme; it acts (much like the lipid-independent form of PKC␦ that accumulates in cells subjected to oxidative stress) to phosphorylate substrates throughout the cell, not just on lipid membranes. This suggests that the ATP-positioning loop site participates in an autoinhibitory intramolecular interaction and that this intramolecular interaction is dynamically controlled by Gloop phosphorylation. This result is consistent with recent structural evidence that the basal catalytic activity of PKC␤II is limited by an autoinhibitory interaction between the ATP binding site and the C1 domain (29) .
Several aspects of our study have implications for the pathogenesis and/or treatment of clinical disease. First, the observation that phosphomimetic and bulky hydrophobic amino acid substitutions at Ser 359 produce similar changes in PKC␦ activity indicates that regulation is due to steric hindrance from the bulky phosphate group, rather than from the negative charge, at this site. This suggests that other bulky substitutions might have similar consequences. This may be pertinent to the diabetic state, where both PKC and increased protein O-GlcNAcylation contribute to cardiac dysfunction (30) . Studies to date suggest that hyperglycemia activates PKC by inducing oxidative stress or increasing de novo DAG synthesis. However, the evidence that Ser 349 in PKC␣'s G loop is a target for O-GlcNAcylation (addition of a bulky sugar moiety [21] ) suggests that PTMs directed at the G loop might also underlie hyperglycemia-induced changes in PKC isoform activity.
Second, while PKC␦-⌬C2 was used in this study as a molecular tool to interrogate the structural determinants that regulate PKC␦ catalytic activity, this construct resembles a truncated PKC␦ isoform that is expressed in a developmentally regulated manner as a result of alternative splicing in mouse testis (31) . Since disease-specific changes in PKC␦ mRNA splicing have recently been identified in certain heart failure phenotypes (32, 33) , a truncated PKC␦ isoform might be a component of the altered cardiac transcriptome that contributes to pathological cardiac stress responses. Finally, this study identifies a protein-protein interaction involving the C2 domain and the Tyr 313 -phosphorylated hinge region that calibrates PKC␦'s substrate specificity by controlling phosphorylation at Ser 359 . This mechanism is prominent during oxidative stress, where Src activation leads to an increase in PKC␦-Tyr 313 phosphorylation; PKC␦-Tyr 313 phosphorylation is not a feature of G protein-coupled receptor-activated signaling responses. Stimulus-specific differences in PKC␦ phosphorylation at Tyr 313 and Ser 359 that impact substrate specificity provide a very plausible explanation for PKC␦'s diverse roles in both the pathogenesis of ischemia-reperfusion injury and as a mediator of ischemic preconditioning (a cardioprotective mechanism that mitigates ischemic injury) (34) . Stimulus-specific signaling modes for PKC␦ that link to functionally distinct cellular responses could also explain why recent efforts to bring a PKC␦ inhibitor compound to the clinic for the treatment of ischemic cardiac injury met with failure; the trial involved a PKC␦ inhibitor that was not designed to discriminate between pools of PKC␦ with distinct phosphorylation patterns at Tyr 313 and Ser 359 . Our results suggest that an inhibitor compound designed to prevent the C2 domainpTyr 313 interaction (and/or Ser 359 dephosphorylation) might selectively block the redox-activated PKC␦-dependent signaling responses that contribute to ischemic injury and offer significant therapeutic advantage.
